Drug Profile
Research programme: pleural effusion therapy - Cumberland Emerging Technologies
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cumberland Emerging Technologies; Vanderbilt University
- Class Transforming growth factors
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pleural effusion
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pleural-effusion in USA (Intrapleural)